Back to Rankings

DLHC

DLHC
Nasdaq / Commercial & Professional Services
Last Price
At close
2026-06-02
View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3
B+
Bull case
25%
Probability
Target price
$8.50
+54.5% vs current
Most likely
B
Base case
45%
Probability
Target price
$6.50
+18.2% vs current
B-
Bear case
30%
Probability
Target price
$4.50
-18.2% vs current

AI sentiment snapshot

Latest data as of 2026-05-09
Recent news sentiment (30D)
-0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+65.4
Score

AI commentary

Primary-source evidence supports a cautious monitoring stance rather than a thesis break. Trusted secondary coverage characterized the print as an EPS and revenue miss versus consensus and reported an immediate stock decline of about 0.9% after the release, while the packet anchor price of $5.73 on 2026-05-07 suggests the follow-through reaction remained modest. News tone is mixed-negative, and the absence of visible post-print analyst revision data keeps conviction low.

RankAlpha Sentiment Codex - 2026-05-09
Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact
standard
Confidence
-

AI events

2026-06-30eventLegacy contract transition should be tested by fiscal Q3 completionHigh impact

Management said the conversion of legacy programs to small-business set-aside contractors is continuing and is expected to complete in the third fiscal quarter, creating a dated checkpoint for whether revenue pressure begins to normalize after June 2026 [#8-K-2026-05-06].

2026-08-31eventQ2 margin defense and cash generation offset part of the earnings resetHigh impact

Fiscal Q2 revenue fell 33.5% year over year to $59.3M and diluted EPS was $(0.17), but adjusted EBITDA margin held at 9.0%, free cash flow was $3.8M, and management said cash generation should accelerate in the second half of fiscal 2026 [#8-K-2026-05-06].

2026-12-31catalystNIH extension helps, but replacement awards still need to outrun backlog erosionHigh impact

DLH reported a two-year sole-source extension for NIH clinical research support, yet backlog was $442.4M at March 31, 2026 versus $514.3M at September 30, 2025, so the longer re-rating case still depends on new awards rebuilding forward coverage [#8-K-2026-05-06].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology